Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Sep 26;11:1179554917731072. doi: 10.1177/1179554917731072

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 3. — Treatment Schema: Early Unfavorable (bulky) Hodgkin Lymphoma.

^aPatients without response should have a biopsy. If biopsy is positive, consider transitioning to a salvage regimen.

^bReimage after 2 cycles of escBEACOPP to ensure response; if no response, consider changing to a salvage regimen.

^cRadiation techniques with smaller fields including involved site irradiation (ISRT) or involved nodal irradiation (INRT) are preferred.

^dBulky disease sites may receive 30 to 36 Gy of RT.

ABVD indicates doxorubicin, bleomycin, vinblastine, dacarbazine; CMT: combination modality therapy; escBEACOPP: escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; PET-CT, positron emission tomography-computed tomography; RT: radiation therapy; Rx: treatment.